JP6920694B2 - ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異 - Google Patents

ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異 Download PDF

Info

Publication number
JP6920694B2
JP6920694B2 JP2018548264A JP2018548264A JP6920694B2 JP 6920694 B2 JP6920694 B2 JP 6920694B2 JP 2018548264 A JP2018548264 A JP 2018548264A JP 2018548264 A JP2018548264 A JP 2018548264A JP 6920694 B2 JP6920694 B2 JP 6920694B2
Authority
JP
Japan
Prior art keywords
protein
hpv11
mutant
amino acid
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018548264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502404A5 (https=
JP2019502404A (ja
Inventor
シャオウェイ リー
シャオウェイ リー
タニン ワン
タニン ワン
シンリン リウ
シンリン リウ
チーハイ リー
チーハイ リー
チュン チャン
チュン チャン
ニンシャオ シア
ニンシャオ シア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Publication of JP2019502404A publication Critical patent/JP2019502404A/ja
Publication of JP2019502404A5 publication Critical patent/JP2019502404A5/ja
Application granted granted Critical
Publication of JP6920694B2 publication Critical patent/JP6920694B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018548264A 2015-12-04 2016-12-02 ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異 Active JP6920694B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510887801.9 2015-12-04
CN201510887801 2015-12-04
PCT/CN2016/108349 WO2017092711A1 (zh) 2015-12-04 2016-12-02 一种人乳头瘤病毒11型l1蛋白的突变体

Publications (3)

Publication Number Publication Date
JP2019502404A JP2019502404A (ja) 2019-01-31
JP2019502404A5 JP2019502404A5 (https=) 2019-08-08
JP6920694B2 true JP6920694B2 (ja) 2021-08-18

Family

ID=58796324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548264A Active JP6920694B2 (ja) 2015-12-04 2016-12-02 ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異

Country Status (6)

Country Link
US (1) US10513541B2 (https=)
EP (1) EP3385274B1 (https=)
JP (1) JP6920694B2 (https=)
KR (1) KR102777995B1 (https=)
CN (1) CN106831958B (https=)
WO (1) WO2017092711A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (zh) * 2019-07-19 2024-04-09 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
WO2021013067A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
BR112022022719A2 (pt) 2020-05-14 2023-02-14 Inovio Pharmaceuticals Inc Vacinas para papilomatose respiratória recorrente e métodos de usar a mesma
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
KR102833970B1 (ko) 2022-02-23 2025-07-17 충남대학교산학협력단 핵수송 신호 펩타이드가 접합된 핵산 전달용 2세대 폴리아미도아민 덴드리머 고분자 유도체
CN116041445B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒51型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5795754A (en) * 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
ATE258222T1 (de) * 1995-11-15 2004-02-15 Merck & Co Inc Synthetische hpv11 virusartige partikel
US5738853A (en) * 1995-11-15 1998-04-14 Merck & Co., Inc. Synthetic HPV11 virus-like particles
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
DK2154149T3 (da) * 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
BRPI0810959B1 (pt) * 2007-05-29 2021-06-29 Xiamen Innovax Biotech Co., Ltd. Proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícula do tipo vírus (vlp) hpv11, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções por hpv e método para produzir uma vacina para prevenção de condiloma acuminado ou infecções por hpv
CN101518647A (zh) * 2008-02-29 2009-09-02 江阴艾托金生物技术有限公司 人乳头瘤病毒预防性疫苗、构建方法及应用
NO2324113T3 (https=) * 2008-08-08 2018-07-28
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN102747047B (zh) * 2012-02-28 2016-03-23 厦门大学 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法
CN104211782B (zh) * 2013-06-04 2017-11-17 厦门大学 截短的人乳头瘤病毒45型l1蛋白

Also Published As

Publication number Publication date
US20190062379A1 (en) 2019-02-28
EP3385274A4 (en) 2019-08-14
BR112018011331A2 (pt) 2019-04-30
JP2019502404A (ja) 2019-01-31
EP3385274B1 (en) 2021-09-22
US10513541B2 (en) 2019-12-24
CN106831958B (zh) 2020-12-29
WO2017092711A1 (zh) 2017-06-08
KR20180084139A (ko) 2018-07-24
CN106831958A (zh) 2017-06-13
KR102777995B1 (ko) 2025-03-10
EP3385274A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
JP6958818B2 (ja) ヒトパピローマウイルスタイプ５８のｌ１タンパク質の突然変異
JP6920694B2 (ja) ヒトパピローマウイルスタイプ１１のｌ１タンパク質の突然変異
JP2023182596A (ja) ヒトパピローマウイルス３９型のｌ１タンパク質の変異体
JP7290258B2 (ja) ヒトパピローマウイルス５１型のｌ１タンパク質の変異型
US11213580B2 (en) Mutant of L1 protein of human papillomavirus type 16
JP7265563B2 (ja) ヒトパピローマウイルス１８型のｌ１タンパク質の変異体
US11464846B2 (en) Mutant of L1 protein of human papillomavirus type 66
BR112018011331B1 (pt) Proteína l1 de hpv11 mutada, partícula semelhante ao vírus hpv, usos das mesmas, ácido nucleico isolado, vetor, célula hospedeira, composições e vacina, e métodos para preparar a proteína l1 de hpv11 mutada e para preparar uma vacina
BR112018011310B1 (pt) Proteína l1 de hpv58 mutada , partícula semelhante ao vírus hpv, usos das mesmas, ácido nucleico, vetor, célula hospedeira, composições ou vacina, e métodos para preparar a proteína l1 de hpv58 mutada e uma vacina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210714

R150 Certificate of patent or registration of utility model

Ref document number: 6920694

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250